DN is the leading cause of end-stage renal disease [1] [2] [3] . Hyperglycemia is known to play a crucial part in the pathogenesis of DN. High glucose levels induce metabolic abnormalities in several glucose metabolic pathways and induce mitochondrial dysfunction, with subsequent overproduction of reactive oxygen species (ROS). These may in turn contribute to the development of the various microvascular pathologies observed in diabetes 4, 5 . Elevated intracellular glucose leads to accumulation of the toxic glucose metabolites sorbitol, methylglyoxal (MG) and diacylglycerol (DAG), which have been proposed to contribute to DN development 6-9 . Furthermore, it has been proposed that mitochondrial dysfunction and ROS production induced by hyperglycemia may be irreversible owing to the persistence of epigenetic reprogramming (namely, metabolic memory) 10, 11 .
a r t i c l e s 7 5 4 VOLUME 23 | NUMBER 6 | JUNE 2017 nature medicine Recent efforts to understand the pathogenesis of diabetic vascular complications have shifted from the identification of risk factors to uncovering endogenous protective factors that might neutralize the adverse effects of hyperglycemia that cause DN or DR. The impetus for the identification of protective factors has been derived from characterization of clinical cohorts that seem to be protected from the development of DN or DR, even with chronic exposure to hyperglycemia. One such study is the Joslin Medalist Study, a longitudinal study of more than 1,000 individuals with type 1 diabetes (T1DM) for more than 50 years, referred to as Medalists. Only 12% of these patients have substantial DN 18, 19 . In the Joslin Medalist Study, neither the presence of DN nor proliferative DR was correlated with glycemic control, which implies that endogenous protective factors may exist to protect individuals from the consequences of chronic hyperglycemia 18, 19 . Thus, the Medalists represent a survival cohort, enriched for individuals who are protected from the development of DN. Indeed, protected individuals within this cohort display only mild renal pathology, despite >50 years of having diabetes. To uncover the mechanism mediating the protection observed in Medalists, we undertook an unbiased approach through proteomic analysis of postmortem glomeruli isolated from the kidneys of Medalists with and without DN. We identified a proteomic signature suggesting that enhanced glycolytic flux might protect glomeruli from the toxic effects of hyperglycemia. The present study tested this hypothesis by increasing glycolytic flux through the use of PKM2 activation in podocytes, and in two interventional rodent models of diabetes.
RESULTS

Elevation of glucose metabolic enzymes in glomeruli from individuals with diabetes but no DN
Proteomics analysis was performed on glomeruli isolated from Medalists by comparing the protected group (no or mild DN; DN class 0-I) to the nonprotected group (severe DN; DN class IIb-III). The renal pathology of each DN class was well correlated with estimated glomerular filtration rate (eGFR) (Supplementary Fig. 1a ). Hemoglobin A1c (HbA1c) was not different between the two groups, in keeping with our previous findings in the Medalist cohort 18, 19 ( Supplementary Tables 1 and 2 ). Our interrogation of the 88 proteins that were significantly upregulated in the protected group (fold change ≥1.5 cutoff; P ≤ 0.05; Supplementary Tables 3 and 4) by geneontology analysis indicated that 7 out of the 12 top-ranked enriched pathways were related to glucose metabolism and glycolysis ( Fig. 1a and Supplementary Table 5) .
Two distinct differential landscapes were observed in the heat map. Protected individuals exhibited higher levels of proteins related to glucose metabolism and antioxidation than nonprotected individuals (Fig.  1b) . Analysis of the upregulated glucose metabolism proteins showed 14 enzymes involved in the processing of free intracellular glucose, including 12 involved in glycolysis and 2 in the TCA cycle. In particular, enzymes from the polyol (AR, aldose reductase; SORD, sorbitol dehydrogenase) and MG (GLO1, glyoxalase 1; hydroxyacyl glutathione hydrolase, HAGH) pathways were upregulated in the protected group (all P < 0.05; Fig. 1c) . Although the glyoxalase system protects cells by eliminating MG, a toxic side product of glycolysis, activation of the sorbitol pathway is surprising because it has been postulated to cause many vascular complications of diabetes, including DN 8, 15 . Taken together, these data show that upregulation of proteins related to glucose metabolism in glomeruli is associated with protection against DN.
The functional effects of the upregulation of these pathways were further elucidated by plasma metabolomic analysis of kidney donors and a living group of Medalists. These two groups share similar characteristics, but exhibit a significant difference in HbA1c (P < 0.0001; Supplementary Table 6 ). Multiple metabolites in the glycolytic, sorbitol and MG detoxification pathways were lower in plasma from the protected group than in that from the nonprotected group, despite the difference in HbA1c of 8.8% relative to 6.5%, respectively ( Supplementary Fig. 1b and Supplementary Table 7 ). The observed reduction in glucose metabolic intermediates in the protected individuals is consistent with an increased ability to process these potentially harmful metabolites.
The schema in Figure 1c illustrates the upregulated proteins in the glucose metabolism and mitochondrial pathways of the protected kidneys as compared to the nonprotected ones. The elevation of the enzymes involved in sorbitol (AR), glycolysis (PKM1, PKM2; ENO1, enolase 1), MG (GLO1) and mitochondrial (MT-CO 2, mitochondrial-encoded cytochrome C oxidase II) pathways were confirmed by immunoblot analysis (Fig. 1d) . The protein levels of these enzymes were higher in the protected group than in the nonprotected group or in age-matched, nondiabetic controls without nephropathy. The assessment of renal pathology was classified according to the Renal Pathology Society's "Pathologic Classification of Diabetic Nephropathy," on the basis of glomerular pathology 20 ( Fig. 1e and Supplementary Table 8) . Among the proteins upregulated in the protected glomeruli, PKM2 was of particular interest because its peptide level was upregulated by 2.7-fold and it is a well-studied enzyme that can be modulated by pharmacological and genetic approaches (P < 0.05; Fig. 1d,f) . Moreover, we observed a correlation of PKM peptide level with eGFR, but not with HbA1c or albumin/ creatinine ratio (ACR) (Fig. 1g and Supplementary Fig. 1c,d ) or association with PKM2 genetic polymorphisms (data not shown). We further performed immunofluorescence staining of PKM2 and the podocyte marker WT-1, endothelial cell marker CD31 and mesangial cell marker α-smooth-muscle actin (α-SMA). We did not observe any substantial change in the number of PKM2 + and CD31 + cells or PKM2 + and α-SMA + cells in the glomeruli when comparing protected and nonprotected kidneys (Supplementary Fig. 2 ). By contrast, there were substantially more PKM2 + and WT-1 + cells in the glomeruli of protected Medalists than in those of the nonprotected group (Supplementary Fig. 2b) . Moreover, preliminary studies on the PKM2 protein levels in the glomeruli of individuals with shorter duration of T1DM and type 2 diabetes (T2DM) indicate a trend toward higher PKM2 levels, by 2.6-fold, in those with no or mild DN as compared to those with DN, but they did not achieve statistical significance ( Supplementary Fig. 3 and Supplementary Table 9 ).
Regulation of PKM2 activity by high glucose and diabetes
In addition to changes in PKM2 protein levels, pyruvate kinase (PK) activity was also determined in glomeruli. Consistent with the higher PKM2 expression, PK activity was elevated in the protected group relative to the nonprotected group (P < 0.05; Fig. 2a) . Furthermore, PK activity was 50% lower in glomeruli from STZ-induced diabetic DBA2/J mice (Fig. 2b) . This is further supported by lower PK activity observed in mouse and human podocytes exposed to high glucose ( Fig. 2c and Supplementary Fig. 4a ). By contrast, PK activity in mesangial or endothelial cells was not affected by high glucose (Supplementary Fig. 4b,c) .
The mechanism of lower PK activity in podocytes exposed to high glucose could be a shift in the distribution of PKM2 from tetramers to dimers and monomers, which are known to be less active than PKM2 tetramers [21] [22] [23] [24] . To assess the status of PKM2 subunit association, cross-linking studies were performed. In agreement with the observed reduction in PK activity, the levels of PKM2 tetramer were lower in glomeruli from mice with diabetes ( Fig. 2d ) and podocytes exposed to high glucose (Fig. 2e) . However, we did not observe any change in protein levels of PKM2 or PKM1 in glomeruli from mice with diabetes or mouse podocytes exposed to high glucose ( Supplementary  Fig. 4d,e) . In addition, pyruvate kinase isozyme liver (PKL) enzyme, which is expressed at a lower level in podocytes, as compared to other PKM isoforms, was also studied. However, we did not observe any change in PKL protein when exposed to high glucose (Supplementary Fig. 4f) .
Prior study has suggested that the oxidation of PKM2 at Cys358 can inhibit its tetramerization, thus reducing its activity 21 . To evaluate the mechanism of high-glucose-induced impairment in PKM2 activity, the levels of oxidized PKM2 were measured. We observed lower levels of sulfenylated and oxidized PKM2 in kidney cortex from the protected group than in the nonprotected group (Fig. 2f) . These data are further supported by elevated PKM2 oxidation in cultured mouse podocytes exposed to high glucose (Fig. 2g) . To confirm whether PKM2 was specifically oxidized at Cys358, we replaced cysteine residue with serine (Ser358) and observed a reduction in sulfenylated PKM2 in podocytes exposed to high glucose (Fig. 2g) . These data collectively suggested that high-glucose-induced oxidative stress may act to reduce PKM2 activity.
The effect of Pkm2 deletion in podocytes on diabetes-induced glomerular abnormalities Several lines of evidences suggest that PKC-δ activation is implicated in cell survival and apoptosis in many cell types [25] [26] [27] . Further, PKC-δ G22 III  G20 III  G18 IIB  G10 III  G5 III  G24 IIB  G29 IIB  G26 IIB  G17 IIB  G12 IIB  G9 IIB  G13 I or IIA  G27 0  G19 I  G7 I  G4 I  G3 I  G15 0   0  5  10  15  20 Glucose metabolic process Nondiabetic controls, n = 5; protected, n = 7; nonprotected, n = 11. M, molecular-weight marker lane. Box plots, center lines represent the median; limits represent quartiles; whiskers represent minimum and maximum values. Comparisons among groups were conducted using analysis of variance (ANOVA). When overall F tests were significant (P < 0.05), post hoc comparisons using Tukey's method of adjustment were conducted to determine the location of any significant pairwise differences. *P < 0.05. induced by high glucose has been shown to induce podocyte apoptosis 25, 27 . Thus, we measured MG and PKC-δ activation in Pkm-knockdown podocytes. Both pathways were increased in Pkm-knockdown cells treated with either low or high glucose (P < 0.005; Fig. 3a,b) . Notably, Ppargc1a (also known as Pgc1α) mRNA, mitochondrial membrane potential (MMP) and mitochondrial mass were all significantly lower in Pkm-knockdown cells (Fig. 3c) . Furthermore, podocyte apoptosis was significantly increased in Pkm-knockdown cells treated with either low or high glucose as compared to scramble-shRNA control (shCntrl) cells in low glucose (Fig. 3d) . To confirm our in vitro findings, we bred a previously described Pkm2 conditional allele (Pkm2 fl/fl ) 28 with podocin-Cre mice to generate podocyte-specific Pkm2-KO mice (PPKM2-KO) (Fig. 3e) . Protein levels of PKM2 were significantly lower, with a compensatory greater level of PKM1, in podocytes isolated from PPKM2-KO mice as compared to wild-type (WT) mice (Fig. 3f) ; thus, PK activity in the mutant mice were normalized to WT level ( Supplementary Fig. 5 ), in keeping with previous characterization of Pkm2-KO mice 28 . PPKM2-KO mice did not differ in fasting blood-glucose levels, body weight, kidney weight or blood pressure when compared to littermate WT mice in either diabetic or nondiabetic conditions ( Fig. 3g and Supplementary  Table 10 ). In keeping with a protective role for PKM2, PPKM2-KO mice with diabetes developed significantly higher levels of albuminuria as compared to WT mice with diabetes ( Fig. 3h) . Histological analysis showed greater mesangial expansion and fibronectin (Fn1, also known as Fn) expression in PPKM2-KO mice with diabetes than in WT mice with diabetes ( Fig. 3i,j) . In summary, Pkm2 deletion in podocytes accelerated mitochondrial dysfunction, podocyte apoptosis and glomerular pathology induced by diabetes.
We further determined the differential effects of PKM1 and PKM2, given that the compensation of PKM1 protein or PK activity could not confer protection from DN in PPKM2-KO mice with diabetes, which could be due to differential actions of PKM1 and PKM2 on the mitochondria. To delineate the mechanisms, we re-expressed PKM1 or PKM2 in podocytes with both Pkm1 and Pkm2 knockdown (PKM kd/M1 or PKM kd/M2) ( Supplementary Fig. 6a-d) . In PKM kd/M2 podocytes, PKM2 was re-expressed to levels similar to those in shCntrl podocytes and normalized mitochondrial mass. By contrast, in PKM kd/M1 podocytes, PKM1 was overexpressed by 40-fold relative to shCntrl podocytes, but resulted in only a modest trend to a higher level in mitochondrial mass, suggesting that PKM2 has a much more potent action than that of PKM1 with respect to the regulation of mitochondrial mass ( Supplementary  Fig. 6e ). Similar findings were observed in MMP: re-expression of PKM2 greatly enhanced its actions, whereas PKM1 overexpression failed to return MMP to shCntrl level ( Supplementary Fig. 6f ). Given that PKM1 may have some effect on mitochondrial metabolism, as shown by its ability to modestly elevate mitochondrial mass and MMP when markedly overexpressed, we further compared the two PKM isoforms by overexpression of PKM1 at lower levels ( Supplementary Fig. 7a-c) . Notably, with a four-fold higher PKM1 expression level in 'PKM1 OE low' relative to WT podocytes, no changes were observed in mitochondrial mass or MMP when compared to empty-vector podocytes ( Supplementary  Fig. 7a-e) . Furthermore, we compared the overexpression of PKM1 (PKM1 OE high; 12-fold higher PKM1 protein level relative to empty vector) to PKM2 (PKM2 OE; four-fold higher PKM2 protein level relative to empty vector) ( Supplementary Fig. 7f-j) , PKM2 overexpression has a substantially greater effect on mitochondrial mass and MMP as compared to WT podocytes or PKM1 OE high podocytes. These data suggest that PKM2 has a more potent and unique mitochondrial effect than PKM1, and this effect might not be the well-described pyruvate kinase glycolytic functions.
The effect of PKM2 activation on glycolysis, mitochondrial metabolism and apoptosis in podocytes Multiple PKM2 activators, including TEPP-46 and those from Agios (PKM2 activator 1020) and Dynamix, (SCHEMBL2694519) increased PK Comparison of more than two groups was analyzed using ANOVA. When overall F tests were significant (P < 0.05), post hoc comparisons using Tukey's method of adjustment were conducted to determine the location of any significant pairwise differences. **P < 0.005; *P < 0.05.
activity in different types of kidney cells (podocytes and proximal tubule cell line, HK-2 cells) (Supplementary Fig. 8 ). TEPP-46 was selected for further study because it has been extensively characterized 21, 24 . We observed that high glucose significantly increased sorbitol, PKC-δ activation and MG levels, and that TEPP-46 or the Agios compound reduced these toxic glucose metabolites to low glucose (LG) levels ( Fig. 4a-c) . To further assess the effect of PKM2 activation on glucose kinetic entry into the podocytes, we measured changes in sorbitol using [U- 13 C 6 ] glucose and DAG by [U-14 C 6 ] glucose. The labeling studies showed that TEPP-46 inhibited the effect of high-glucose-mediated increases in the levels of 13 C-labeled sorbitol and 14 C-labeled DAG levels in cultured podocytes (Fig. 4d,e) . Because the activation of PKM2 seemed to increase glycolysis and mitochondrial biogenesis, the effect of TEPP-46 on glycolytic and mitochondrial flux in podocytes was determined. Prolonged incubation of podocytes with high glucose decreased glycolytic flux (ECAR) and mitochondrial function (OCR). Notably, TEPP-46 reversed the high-glucose-induced impairments in glycolytic flux and basal and maximal mitochondrial respiration (Fig. 4f) . These data were further confirmed by CO 2 production, specifically from the TCA cycle, using [6-14 C] glucose ( Fig. 4g) and by an increase in adenosine triphosphate (ATP) levels with the addition of TEPP-46 (Fig. 4h) .
In line with the increased oxidative phosphorylation induced by TEPP-46, elevation of mitochondrial mass and MMP were also observed ( Fig. 4i and Supplementary Fig. 9a,b) . By contrast, TEPP-46 failed to normalize the inhibitory actions induced by high glucose on mitochondrial metabolism in Pkm-knockdown podocytes, which suggests that the actions of TEPP-46 require PKM expression (Fig. 4j) . TEPP-46 increased Ppargc1a mRNA expression in podocytes treated with either low or high glucose ( Fig. 4k and Supplementary Fig. 9c ). The ability of PKM2 activation to induce Ppargc1a expression was confirmed using PKM2 activators from Agios and Dynamix (Supplementary Fig. 10d ). These data are further supported by a more than four-fold elevation of Ppargc1a mRNA expression in podocytes overexpressing PKM2 (Supplementary Fig. 9e ). In podocytes with Ppargc1a knockdown, TEPP-46 failed to increase mitochondrial mass (Supplementary Fig. 9f ). By contrast, TEPP-46 continued to increase MMP in Ppargc1a knockdown podocytes, which suggests that the effect of TEPP-46 is independent of PGC-1α ( Supplementary  Fig. 9g) . The results suggest that PKM2 activation by TEPP-46 may exert its mitochondrial biogenesis effect through different pathways, with some actions mediated by transcriptional changes in the nucleus and others by direct actions of PKM2 on the mitochondria.
Notably, we observed that PKM2 activation by TEPP-46 also prevented high-glucose-induced elevation of ROS production, cytochrome c release and podocyte apoptosis (Fig. 4l-n) ; these changes were reversed in an intervention study (Supplementary Fig. 10 ). ; nondiabetic PPKM2-KO mice (n = 6); diabetic WT mice (n = 5); diabetic PPKM2-KO mice (n = 6). For box plots (g,h,i,j), center lines represent the median; limits represent quartiles; whiskers represent minimum and maximum values. All values are means ± s.e.m. in bar graphs. All data throughout this figure are analyzed using ANOVA. When overall F tests were significant (P < 0.05), post hoc comparisons using Tukey's method of adjustment were conducted to determine the location of any significant pairwise differences. ***P < 0.001; **P < 0.005; *P < 0.05. # P = 0.068.
The ability of TEPP-46 to reverse the toxic effects of high glucose on podocytes after chronic hyperglycemia exposure suggests that PKM2 activation can reverse the metabolic and biochemical changes induced by high glucose, namely metabolic memory, and promote podocyte survival in high-glucose conditions.
PKM2 activation reversed abnormalities in glucose and mitochondrial metabolism in diabetes To determine its effects in vivo, TEPP-46 was given to mice in a daily oral gavage. We observed a substantial increase in PK activity in the kidney cortex after 24 h of TEPP-46 exposure (Supplementary Fig. 11) .
In intervention studies, TEPP-46 was not given to mice with diabetes until 3 months after disease induction (Fig. 5a) . No differences were observed in blood glucose levels, body weights or blood pressure between vehicle-treated or TEPP-46-treated mice with diabetes after 3 months of treatment (Supplementary Table 11 ). At 6 months after the induction of diabetes, TEPP-46 lowered sorbitol, DAG (C16:0/18:0) and MG in diabetic mice and notably restored these metabolites to nondiabetic levels (all P < 0.05; Fig. 5b-d) .
In agreement with the in vitro data, Ppargc1a mRNA levels were significantly lower in glomeruli from diabetic mice treated with vehicle. By contrast, TEPP-46 restored Ppargc1a expression to nondiabetic levels after 3 months of TEPP-46 treatment (Fig. 5e) . Furthermore, TEPP-46 treatment induced the expression of Opa1, a gene that LG-vehicle, n = 8; HG-vehicle, n = 10; LG-TEPP-46, n = 5; HG-TEPP-46, n = 9. (n) Podocytes treated for 72 h. Independent experiments n = 4. All values are means ± s.e.m. ***P < 0.001; **P < 0.005; *P < 0.05. All data throughout this figure are analyzed using ANOVA. When overall F tests were significant (P < 0.05), post hoc comparisons using Tukey's method of adjustment were conducted to determine the location of any significant pairwise differences.
encodes for a reported mitochondrial fusion protein 29 , to nondiabetic levels in the diabetic glomeruli and tubules (P < 0.05; Fig. 5e ), which suggests that PKM2 activation may promote mitochondrial fusion. These data are supported by electron microscopy showing that mice with diabetes had smaller and more punctate mitochondria in podocytes when compared to those in nondiabetic mice. Mitochondria number was 49% lower in diabetic mice treated with TEPP-46 as compared to vehicle-treated mice with diabetes. Conversely, mitochondria size was 1.69-fold larger in diabetic mice treated with TEPP-46 (P < 0.001; Fig. 5f ), which indicates an elevation of mitochondrial fusion in TEPP-46-treated mice with diabetes. To provide additional evidence that the effect of TEPP-46 on Ppargc1α expression is a PKM2-specific effect, we isolated primary podocytes from PPKM2-KO and WT mice and treated them with TEPP-46. We did not observe any elevated Ppargc1α expression in podocytes with Pkm2 deletion, which suggests that the action of TEPP-46 on Ppargc1α expression is dependent on PKM2 activation (Fig. 5g) . Notably, we observed that TEPP-46 reversed the elevated ACR in diabetic mice in an intervention study. However, TEPP-46 treatment was ineffective in PPKM2-KO mice, further confirming that its effects occur in PKM2-specific manner ( Fig. 5h and Supplementary Fig. 12a ).
Pharmacologically activating PKM2 prevents the development of glomerular pathology
We studied the effect of PKM2 activation by TEPP-46 on the progression of renal abnormalities and glomerular pathology in STZ-induced diabetic DBA2/J mice using intervention studies with TEPP-46 for 3 months after the onset of diabetes. Blood urea nitrogen (BUN), creatinine, lipids, liver enzymes and blood cell counts were unaffected by TEPP-46 treatments. Furthermore, 6 months of STZ-induced diabetes did not cause any substantial elevations of plasma creatinine or BUN (Supplementary Table 12) . After 3 months of diabetes, TEPP-46 treatment for 1 month and 3 months reduced albuminuria (ACR) as compared to diabetic mice treated with vehicle (P < 0.05; Fig. 6a ). TEPP-46 attenuated mesangial expansion (Fig. 6b) and significantly reduced fibronectin mRNA expression in both diabetic glomeruli and tubules (Fig. 6c) . In addition, other extracellular matrix (ECM)-associated genes were significantly lower in the tubules from TEPP-46-treated mice with diabetes (Fig. 6c) . Glomerular basement membrane (GBM) thickening, a hallmark of DN, was also reduced in TEPP-46-treated diabetic mice relative to that in vehicle-treated mice with diabetes (P < 0.001; Fig. 6b) . Conversely, podocyte number was notably increased in TEPP-46-treated diabetic mice as compared to vehicle-treated diabetic mice (P < 0.05; Fig. 6d) .
We have further confirmed the beneficial effects of TEPP-46 by using an STZ-treated eNos (nitric oxide synthase 3, endothelial cell) KO mouse model 30, 31 (Supplementary Fig. 12b-d and Supplementary  Table 13 ). TEPP-46 treatment also reduced albuminuria (Fig. 6e) , mesangial expansion and the expression of ECM genes in eNos KO mice with diabetes (Fig. 6f,g ). These data collectively suggest that PKM2 activation can reverse renal abnormalities and kidney pathology induced by diabetes.
DISCUSSION
This is the first proteomic analysis of glomeruli from individuals with extreme duration of diabetes but protected from DN, which allows for the identification of potential protective factors against the toxic effects of hyperglycemia. The detailed interrogation of the differentially expressed glomerular proteins shows a strong clustering of enzymes in pathways related to glycolysis, sorbitol, MG and All data throughout this figure are analyzed using ANOVA. When overall F tests were significant (P < 0.05), post hoc comparisons using Tukey's method of adjustment were conducted to determine the location of any significant pairwise differences. ***P < 0.001; **P < 0.005; *P < 0.05.
mitochondrial function in the protected kidneys. The elevation of multiple enzymes involved in glucose metabolism, with correspondingly lower levels of plasma metabolites from these pathways in the protected group, even with elevated HbA1c, suggests that a reduction of free intracellular glucose and its metabolites can preserve glomerular function. The presence of elevated levels of aldose reductase and sorbitol dehydrogenase may enhance the metabolism of excess intracellular free glucose, which could protect podocytes and glomeruli from hyperglycemic toxicity. This is contrary to the hypothesis that their activation is pathogenic for diabetic vascular complications 8, 15 . The glomerular proteomic profiling suggests that increased metabolic flux through glycolysis could neutralize the toxic effects of hyperglycemia, and so we tested whether pharmacologically activating PKM2 can increase flux through glycolysis. The elevated levels of MG, PKC-δ activation and apoptosis in Pkm-knockdown podocytes mimic the effects of diabetes. Additionally, PKM2 activation normalizes high-glucose-induced elevation of these toxic glucose metabolites in podocytes, simulating the findings from the protected Medalists. Results from studies using stable and radioactive isotopes and the Seahorse Flux Analyzer support our hypothesis that increased flux through glycolysis by PKM2 activation in podocytes will lower the accumulation of toxic glucose-derived end products, increase flux through the TCA cycle and improve mitochondrial function. However, the protective properties of glycolytic flux are likely to be relative, because extreme or prolonged hyperglycemia will likely overwhelm the protective capacity of this mechanism. Notably, we have confirmed the specificity of TEPP-46 on mitochondrial metabolism in podocytes and ACR in mice with podocyte-specific deletion of Pkm2 (PPKM2-KO mice). It is interesting that increased glycolytic flux does not cause mitochondrial dysfunction, a common feature in diabetic vascular tissues 5, 32, 33 . Rather, these findings suggest that increased glycolytic activity in podocytes may even partially preserve mitochondrial function. Interestingly, a previous study using human and mouse models of kidney fibrosis reports that enzymes from the glycolytic and mitochondrial metabolism are also lower in the fibrotic tubules 34 .
Notably, the activation of PKM2 improves and even reverses mitochondrial dysfunction by increasing mitochondrial metabolism, including levels of PGC-1α, MMP and mitochondrial mass. This finding is particularly interesting in light of the fact that mitochondrial dysfunction has been proposed as a major defect induced by hyperglycemia, which leads to cellular dysfunction and pathology in multiple vascular tissues, including the glomeruli 5, 13, 32, 35 . The mechanism by which the activation of PKM2 improves mitochondrial function could be related to enhancing OPA1, which has been reported to induce mitochondrial fusion 29 . Mitochondrial dysfunctions induced All data throughout this figure are analyzed using ANOVA. When overall F tests were significant (P < 0.05), post hoc comparisons using Tukey's method of adjustment were conducted to determine the location of any significant pairwise differences. ***P < 0.001; **P < 0.005; *P < 0.05.
by diabetes and high glucose were reversible with the use of PKM2 activators, further suggesting that epigenetic abnormalities known to cause mitochondrial dysfunction and metabolic memory in diabetes could be reversed 5, 11, 13, 32, 35, 36 . The normalization of mitochondrial dysfunction seems to be PKM2 specific, given that TEPP-46 does not induce PGC-1α in podocytes with Pkm2 deletion. Furthermore, our findings indicate that elevated oxidant production induced by high glucose can be reduced by PKM2 activators, which again supports the idea that PKM2 activation may improve mitochondrial function.
Observations of glucose flux, as measured either by glycolysis or mitochondrial function, also support the idea that high-glucose-induced or diabetes-induced mitochondrial dysfunction could be improved by PKM2 activation associated with increasing flux through glycolysis. It is not surprising that the compensatory elevation in PKM1 expression and PK activity exhibited in diabetic PPKM2-KO mice fails to protect them from DN development, because many reports have showed that PKM1 and PKM2 have different cellular functions 37, 38 . Our findings from the rescue experiments of re-expressing PKM1 or PKM2 in Pkm-knockdown podocytes clearly demonstrate that these two isoforms have differential actions on mitochondrial function. Moreover, the differential actions of PKM1 and PKM2 might not be limited to the well-described pyruvate kinase glycolytic functions. Several reports of studies on transformed cells have suggested that PKM2 can function as a protein kinase in addition to its glycolytic functions, and translocate to the nucleus 24, [39] [40] [41] [42] . Unlike PKM1, the structural configuration of PKM2 can be regulated by glucose metabolites and cellular signaling events 22, [43] [44] [45] . Our results have suggested that PKM2 has a more potent and unique effect on mitochondrial biogenesis than PKM1 when it is overexpressed in podocytes at basal physiological conditions. Extreme overexpression of PKM1 did modestly enhance mitochondrial function in the absence of PKM2. However, it is not clear whether extremely overexpressed PKM1 may occupy subcellular sites at which only PKM2 normally exists, thereby mediating the selective properties of PKM2. Further studies will be needed to confirm this hypothesis.
One potential explanation for the lower levels in some of the 14 glycolytic enzymes from the nonprotected group could be the contribution of podocyte loss, the replacement by other types of cells and extracellular matrix proteins. However, several of our findings suggest that may not be the primary explanation. We observed that these glycolytic and mitochondrial enzymes were lower in the glomeruli from nondiabetic donors without nephropathy than in those from protected Medalists. Furthermore, PK activity was also decreased in cultured podocytes exposed to high glucose and in glomeruli isolated from diabetic mice after 2 months, when podocyte loss is not significant. Additionally, other glomerular cells that replace podocytes in the fibrotic kidneys also express many of the glycolytic and mitochondrial enzymes, as observed in the glomerular proteomics from the Medalist cohort.
In our Medalist studies, we cannot exclude the possibility that nonprotected individuals are actually partially protected, given that they have survived living with T1DM for more than 50 years. Typical DN in T1DM appears 5-15 years after the onset of diabetes. Our histological analysis of the nonprotected individuals is consistent with changes observed in DN. But the mechanisms underlying this nonclassical form of DN may be different from those with the usual presentation of DN. Further studies on a larger sample size of subjects with multiple stages of DN and shorter durations of both T1DM and T2DM will be needed to determine whether the findings from this study are also observed in individuals with classical presentation of DN.
Interestingly, preliminary studies on PKM2 protein levels in the glomeruli from subjects with shorter durations of T1DM and T2DM indicate a trend toward higher PKM2 levels in those with no or mild DN by 2.6-fold, when compared to DN, without achieving statistical significance. It is surprising that the expression of PKM2 was already higher in those with no or mild DN than those with DN in so few samples, given that the expectation is for few individuals with diabetes to have the 'protective' protein profile observed in the Medalists. Thus, it is likely that other factors, such as persistent good glycemic control, can also preserve some of the protective protein profile. As noted above, further studies on a larger sample size of subjects with shorter duration of both T1DM and T2DM will be needed to determine PKM2 levels in a general diabetic population.
In intervention studies, the activation of PKM2 by TEPP-46 clearly improves the pathological outcomes of glomerulopathy in diabetic mice. These results from intervention models are critical given that clinical studies will likely be interventional, owing to the high cost of prevention trials for DN. It is noted that mouse models for DN do not mimic human DN because they do not develop renal failure (end-stage renal disease) [46] [47] [48] . However, our study has clearly shown that treatments with TEPP-46 after 3 months of diabetes can reverse many early biochemical and cellular abnormalities that subsequently lead to a reduction of ACR, mesangial expansion, basementmembrane thickening and fibrosis in both glomeruli and tubules. This is confirmed by using two rodent models of DN, including STZinduced diabetic DBA2/J mice and diabetic eNos KO mice 30, 31, [47] [48] [49] . In conclusion, these findings suggest that PKM2 is a novel therapeutic target identified in glomeruli isolated from individuals with diabetes, and that its activation prevents DN progression by reducing levels of toxic glucose metabolites and inducing mitochondrial biogenesis, despite the presence of diabetes.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
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Mouse metabolic measurements. Blood glucose levels were measured from tail-vein blood using contour (Bayer). Blood pressure was assessed by tail-cuff method (Visitech Systems noninvasive blood-pressure analysis system). In DBA2/J mice study, spot urine was collected. In PPKM2-KO and eNos KO mice study, urine was collected from 24-h metabolic caging. Albuminuria was quantified by albumin and creatinine ratio (ACR) using Albuwell M and the Creatinine Companion kits (Exocell Mouse glomeruli isolation. Glomeruli were isolated using magnetic Dynabeads method as previously described 61 with some modifications. In brief, Dynabeads M-450 Tosylactivated (Invitrogen, #14013) was perfused from the mouse aorta and minced kidney tissues were digested in 1 mg/ml collagenase A and 100 U/ml DNase I for 30 min. Digested mixture was then passed through a 100-µm cell strainer, and the flow-through was then placed on a magnet for purification. The purity of glomeruli was confirmed to be 95% in each sample by phasecontrast microscopy.
Mouse kidney pathology assessment. We used 4-µm sections from kidneys processed with paraformaldehyde-fixed and paraffin-embedded for PAS staining and immunohistochemistry staining of WT-1. Mesangial expansion was assessed in PAS-stained kidney sections as described by others 48, [62] [63] [64] [65] . A semiquantitative score (sclerosis index (SI)) was used to evaluate the degree and extent of glomerular sclerosis as previously described. In immunohistochemistry staining of WT-1, 60-91 glomeruli from each group were assessed in a masked manner.
Transmission electron microscopy. The complete method is previously described 66 . Kidney tissue samples were fixed in 2.5% glutaraldehyde in 0.1-M phosphate buffer and processed for routine electron microscopy. Images were obtained using Philips 301 Transmission Electron Microscope. For GBM measurement, there were 100 measurements for each mouse and n = 6 mice per group. For mitochondrial studies, more than 300 mitochondria were examined from each group comprising 5-7 mice. ImageJ was used for all the measurements.
Statistical analysis.
Figures were produced using GraphPad prism software. Animals were randomly assigned to groups. In mouse and clinical studies, histological analysis was conducted in a blinded manner. Based on extensive experience with these mouse models of diabetes (for example, assay sensitivity, the different animal strains used, mortality rate) and given the planned analytical framework, we estimated the number of mice per group that would be required to detect effects of interest at the P < 0.05 level of significance. The numbers of technical replicates or biological replicates (independent experiments for cell culture, or individual mouse for in vivo) in each group were stated in figure legends. All data are presented as either means ± s.e.m. or means ± s.d., as stated in figure legends. Unpaired Student's t-tests with no assumption of equal variance were used for comparisons between two groups. To determine goodness of fit correlation (R 2 ), univariate linear regression was used. For comparisons of more than two groups, ANOVA (by general linear model) was used. When overall F tests were significant (P < 0.05), post hoc comparisons using Tukey's method of adjustment were conducted to determine the location of any significant pairwise differences. Analysis was performed using SAS v9.4 (Cary, NC) and GraphPad prism 5.02 software (La Jolla, CA). A two-sided P value < 0.05 was considered to be statistically significant. Diabetic mice were excluded from the analysis if their body weight was less than the body weight at 8 weeks old before STZ injection or if they died before the end of the designated study period. The exclusion criteria were based on the pre-established requirements that the metabolic abnormalities and pathology observed in mice with significant weight loss are not reliable and could be due to starvation effects. For the STZ-induced diabetic DBA2/J mouse study, kidneys from diabetic mice with systemic infections were excluded from the analysis. 18/58 diabetic DBA2/J mice were excluded from the study. The exclusion included mice with systemic infection and those that died before the end of the designed study period. 
